VANCOUVER, Sept. 25, 2019 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announced
that its Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will represent
Sirona at Cosmetic 360 in Paris,
October 16-17, 2019. Since 2015,
Cosmetic 360 has become an exclusive international event that
allows the most influential cosmetic companies and industry
decision makers to access the latest advancements in science.
Dr. Deliencourt-Godefroy will be joined by lab colleague Dr.
Jocelyne Legoedec as well as Ms. Michelle
Seltenrich, Vice President Operations, to present the most
recent advancements of Sirona's novel skin lightener, TFC-1067.
Additional detailed clinical results will be available, and the
team will have the opportunity to meet one-on-one with
international skincare companies and explore potential
collaborations for this innovative compound. Thanks to compelling
clinical evidence of superiority to selectively remove dark spots
in comparison to a leading brand containing hydroquinone, previous
challenges to partnering have been overcome and Sirona is now well
positioned with TFC-1067.
"Our recently completed licensing and supply agreement with
Rodan + Fields validated our science and confirmed the Company's
ability to commercialize TFC-1067. This puts us in a much stronger
position when entering discussions with companies interested in
this compound. We anticipate significant interest in Europe where hydroquinone is banned because of
its toxicity. Michelle Seltenrich
has been involved in licensing and M&A throughout her career
and was instrumental in completing the Rodan + Fields agreement
beginning with the very first introductory meetings through to its
successful completion. I have chosen the current team with great
confidence they will open doors to a new partnering opportunity for
TFC-1067," said Dr. Howard Verrico,
CEO of Sirona Biochem.
"With TFChem being based in France and the tremendous government support
we receive, there is great excitement in attending Cosmetic 360.
This event is also sponsored in part by Rodan + Fields. In the
past, interested companies have looked for clinical proof of
efficacy for TFC-1067. We now have that, and I anticipate this to
be an outstanding opportunity to showcase our achievements,"
reports Dr. Deliencourt-Godefroy. "We are fully committed and
dedicated to expanding the commercial opportunities to bring
TFC-1067 to the global marketplace, and this is our primary focus
in attending Cosmetic 360," said Dr. Deliencourt-Godefroy.
About Cosmetic 360
Cosmetic 360 is an innovative-centered trade fair for the
cosmetic industry. The conference brings together professionals and
industry representatives from all over the world. All facets of the
cosmetic industry are represented at the conference including raw
materials, formulation, packaging, testing and analysis, finished
products, and distribution. More information on the conference can
be found at www.cosmetic-360.com/en.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.